DRSCREEN: Developing a computer-based image processing system for diabetic retinopathy screening
The aim of the project is to develop an automated image analysing system for retinopathy screening (ophthalmological application). The function of the system being developed in the project is to separate the pathological and the normal retina by the digital images. We would like to use the system in the frame of the "English National Screening Programme for diabetic retinopathy" and other similar screening programs in the future. The system is able to pre-screen the patients without the contribution of professional staff. Only those patients who were found positive by the system will be directed to medical examination, reducing the burden of health care system. Moorfields Eye Hospital (London, England) – one of the most prestigious eye clinic in the world - will be involved in the research and the clinical validation. Partners: University of Debrecen and 3T Research For more information on the project please visit: http://www.drscreen.eu |  |
 | SCHIZO: Biobank based biomarker discovery and molecular mechanism research to support antipsychotic drug development
The aim of the project is to develop biomarkers and methods to support, rationalize and accelerate the discovery and development of novel drugs for the treatment of psychotic disorders. As a result more effective drugs with fewer side effects than the existing ones can be put on the market. Partners: Gedeon Richter, University of Debrecen, UD-Genomed, Hungarian Clinical Neurogenetic Society For more information on the project please visit: http://www.schizobank.eu |
Joint Research on Melanoma Therapy
Melanoma is an aggressive malignancy with a continuously increasing incidence – and unfortunately with limited therapeutic potentials. The first aim of the project is to develop a state-of-the-art bioinformatics tool to predict and optimize the expression profile and the behavioural pattern of the target melanoma cells effecting RNA-based vectors. The second aim is to determine optimized RNA-based vectors for melanoma vaccination using the bioinformatic tool developed. Immunomodulation and direct targeting of signaling pathways in malignant melanoma are promising directions in melanoma therapy research. Preliminary results are convincing: upon administration of the compound, a longer survival period and a better progression rate was observed in mice. After modifications identified and carried out through the collaborative work, enhanced efficiency is hoped to be attained. Later on a clinical trial might be initiated. Partner: Molecular Biophysics Institute at the CNRS campus of Orléans |  |